Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | RARB | P10826 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | STAT3 | P40763 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5750627 | 0.98 | RAB9A (0.53) | RAB9AMAPTKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL5749047 | 0.98 | RAB9A (0.53) | RAB9AMAPTKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL5748785 | 0.98 | RAB9A (0.53) | RAB9AMAPTKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL6615395 | 0.84 | NPC1 (0.41) | RAB9AMAPTKDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL6417146 | 0.80 | RARB (0.47) | RAB9AMAPTKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL12186163 | 0.78 | RARB (0.50) | RAB9AMAPTKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL7910575 | 0.78 | PTGS2 (0.52) | RAB9AMAPTKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL1577302 | 0.78 | RARB (0.46) | RAB9AMAPTKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL12186156 | 0.78 | RARB (0.50) | RAB9AMAPTKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL2249764 | 0.78 | RARB (0.46) | RAB9AMAPTKDM4ESMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090074886-A1 | GSK-3 INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS INC. | 2009-03-19 | — | — | US | disclosed |
| EP-1653970-A4 | GSK-3 INHIBITORS AND USES THEREOF | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-10-15 | — | — | EP | disclosed |
| US-7425557-B2 | Inhibitors of glycogen synthase kinase 3 | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-09-16 | — | — | US | disclosed |
| CN-1835755-A | GSK-3 inhibitors and uses thereof | CHIRON CORP (US) | 2006-09-20 | — | — | CN | disclosed |
| US-7045519-B2 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2006-05-16 | — | — | US | disclosed |
| EP-1653970-A2 | GSK-3 INHIBITORS AND USES THEREOF | CHIRON CORPORATION (US) | 2006-05-10 | — | — | EP | disclosed |
| US-7037918-B2 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2006-05-02 | — | — | US | disclosed |
| US-20060089369-A1 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2006-04-27 | — | — | US | disclosed |
| WO-2005039485-A2 | GSK-3 INHIBITORS AND USES THEREOF | CHIRON CORPORATION (US) | 2005-05-06 | — | — | WO | disclosed |
| US-20050054663-A1 | Bone disorders; osteoporosis | CHIRON CORPORATION | 2005-03-10 | — | — | US | disclosed |
| EP-1087963-B1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORP (US) | 2004-08-25 | — | — | EP | disclosed |
| US-20030130289-A1 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION | 2003-07-10 | — | — | US | disclosed |
| EP-1317433-A2 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2003-06-11 | — | — | EP | disclosed |
| US-6489344-B1 | FOR TREATMENT DIABETES IN A HUMAN OR ANIMAL SUBJECT | CHIRON CORPORATION | 2002-12-03 | — | — | US | disclosed |
| US-20020156087-A1 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION | 2002-10-24 | — | — | US | disclosed |
| US-6417185-B1 | HETEROCYCLIC ENZYME INHIBITORS | CHIRON CORPORATION | 2002-07-09 | — | — | US | disclosed |
| WO-2002020495-A2 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2002-03-14 | — | — | WO | disclosed |
| EP-1087963-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | Chiron Corporation (US) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999065897-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054663-A1 | Bone disorders; osteoporosis | GSK3B, GSK3A, GSKIP | RAB9A 2438/4885MAPT 1221/4885KDM4E 1414/4885 |
| US-20030130289-A1 | Inhibitors of glycogen synthase kinase 3 | GSK3B, GSK3A, PYGB | RAB9A 4060/4885MAPT 134/4885KDM4E 2320/4885 |
| US-20060089369-A1 | Inhibitors of glycogen synthase kinase 3 | GSK3B, GSK3A, PYGB | RAB9A 4093/4885MAPT 146/4885KDM4E 2567/4885 |
| US-20090074886-A1 | GSK-3 INHIBITORS | GSK3B, GSK3A, GSKIP | RAB9A 3201/4885MAPT 594/4885KDM4E 1258/4885 |
| US-20020156087-A1 | Inhibitors of glycogen synthase kinase 3 | GSK3B, GSK3A, PYGB | RAB9A 4093/4885MAPT 146/4885KDM4E 2567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.